Bridging Science and Business for Smarter Biotech Decisions
Independent consulting that transforms discoveries into market-ready opportunities
Biotech Consulting Services
Where science meets strategy, across borders.
ArgoScientia brings together world-class biotech consultants with a proven track record at the intersection of science, business, and investment. With operations in both the United States and Europe, we offer clients a unique advantage: the ability to navigate and connect the two most important biotech markets in the world.
With close to $2B in preclinical-stage transactions supported, our team has the experience, credibility, and global reach to guide high-stakes decisions across the innovation landscape. We deliver rigorous, independent perspectives that help organizations evaluate, prioritize, and advance life science opportunities with clarity and confidence.
Whether you’re an academic center advancing disclosures, a biotech preparing for its next raise, or an investor seeking targeted support, ArgoScientia offers tailored support that moves innovation forward.
Meet the Founders
Javier Iglesias-Gonzalez, PhD
Javier leverages a rare blend of scientific rigor, entrepreneurial drive, and global perspective to help transform life science innovations into real-world impact. He has led business development and strategic evaluation for academic institutions and biotechs, including extended work with Mount Sinai in New York, and recently founded MitoKrib with Alan to advance a therapy for a rare pediatric disease.
He began his career as a principal investigator in mitochondrial bioenergetics and oxidative stress research in Europe. In parallel, he’s guided early-stage product launches, secured non‑dilutive funding, and steered technology transfer initiatives, giving him first-hand insight into what investors and partners look for in both commercial and institutional collaborations.
Javier is located in Spain and bridges the U.S. and European biotech ecosystems with hands-on experience in academic discovery, business development, and technology commercialization. He is passionate about delivering independent, scientifically grounded counsel that moves both science and strategy forward.
Alan Belicha, PhD
Alan is a biotech entrepreneur and business development executive with broad experience across the life sciences, from infectious disease to oncology and rare genetic disorders. He has worked across academic, nonprofit, and commercial settings to help early-stage innovations move from concept to clinic.
He has held business development roles at Santa Ana Bio and Chameleon Biosciences, and served as a consultant to venture firms including Versant Ventures and Ascent Biomedical Ventures. Alan has also led a $47.5 million life sciences economic development fund focused on advancing regional innovation and job creation in Upstate New York.
As founder of MitoPath and MitoKrib, Alan has helped build and lead companies focused on rare diseases, with an emphasis on translating academic discoveries into commercially viable therapies. He has worked closely with leading academic institutions across the United States, Europe, and South America, supporting technology evaluation, licensing, and partnering efforts.
Based in New York City, Alan frequently travels to Europe and attends major industry gatherings, such as the J.P. Morgan Healthcare Conference and the BIO International Convention, to represent clients and cultivate ArgoScientia’s global network.
